All In Biotech

Free tool

FAERS Monitor: Trodelvy

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761115 or its brand name (Trodelvy, Sacituzumab Govitecan-Hziy). Reports on generic versions are filed under their own applications.

Reports

4,834

Serious

4,329

90% of reports

Hospitalization

1,310

Death reported

1,014

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • disease progression1,368
  • diarrhoea615
  • neutropenia549
  • death491
  • nausea281
  • fatigue273
  • triple negative breast cancer229
  • febrile neutropenia219
  • asthenia217
  • off label use207
  • alopecia176
  • inappropriate schedule of product administration170
  • neutrophil count decreased148
  • thrombocytopenia147
  • vomiting145

Reports by year received

View as table
YearReports
20192
2020112
2021397
20221,248
2023579
2024714
2025967
2026815

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,325 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
triple negative breast cancerSignal2292245.91919.7337,532
disease progressionSignal1,36850.948.666,447
neutropeniaSignal54917.616.38,619
neutrophil count decreasedSignal14815.913.52,041
febrile neutropeniaSignal21914.412.72,719
thrombocytopeniaSignal1475.74.9571
diarrhoeaSignal6154.13.91,511
inappropriate schedule of product administrationSignal1704.13.5400
alopeciaSignal1763.93.4380
astheniaSignal2172.52.2199
deathSignal4912.52.3451
nausea2811.51.456
fatigue2731.51.451
vomiting1451.31.113
off label use2071.00.90

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.